Menichetti F, Del Favero A, Bucaneve G, Aversa F, Baldelli F, Felicini R, Terenzi A, Pauluzzi S
Institute of Infectious Disease, University of Perugia Medical School, Italy.
J Antimicrob Chemother. 1988 Jan;21 Suppl A:105-11. doi: 10.1093/jac/21.suppl_a.105.
Teicoplanin in combination with amikacin and ceftazidime was used as empirical therapy in treating 46 febrile episodes in 34 consecutive patients undergoing allogenic bone marrow transplantation. All but four of these febrile episodes occurred in neutropenic patients and 50% of them proved to be bacteraemias (23/46). Cure was achieved in 90% of Gram-positive bacteraemias (18/20) and in six of them teicoplanin was the only antibiotic with activity in vitro against the infecting strain. All (3/3) Gram-negative bacteraemias were cured. Central venous catheter removal was required in five patients (three tunnel infections, one exit-site infection and one thrombophlebitis). Two failures occurred among Gram-positive bacteraemias and in one case the patient died of infection. Four instances of side effects were documented but only one was severe (hearing loss).
替考拉宁联合阿米卡星和头孢他啶被用作经验性治疗，用于治疗34例接受异基因骨髓移植的连续患者中的46次发热发作。除4次发热发作外，其余均发生在中性粒细胞减少的患者中，其中50%被证实为菌血症（23/46）。90%的革兰氏阳性菌血症（18/20）得到治愈，其中6例替考拉宁是唯一对感染菌株具有体外活性的抗生素。所有（3/3）革兰氏阴性菌血症均被治愈。5例患者需要拔除中心静脉导管（3例隧道感染、1例出口部位感染和1例血栓性静脉炎）。革兰氏阳性菌血症中有2例治疗失败，其中1例患者死于感染。记录到4例副作用，但只有1例严重（听力丧失）。
